Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
Michael HaasePaul LesnyMark AndersonGavin ClohertyMichael StecAnja Haase-FielitzMathias HaarhausCarla Santos-AraújoPedro Mota VeigaFernando MacarioPublished in: Journal of nephrology (2022)
Within the limitations of this study, heterologous vaccination with ChAd/BNT appears to induce stronger humoral immunity and more frequent but manageable side effects than homologous vaccination with BNT/BNT or with ChAd/ChAd in COVID-19-naïve hemodialysis patients.